cream for genital warts Notice!

Patients Being Treated for Actinic Keratosis (AK)

Dosing is 2 times per week for a full 16 weeks, unless otherwise directed by the physician. However, the treatment period should not be extended beyond 16 weeks due to missed doses or rest periods .

It is recommended that the treatment area be washed with mild soap and water 8 hours following Aldara Cream application.

Most patients using Aldara Cream for the treatment of AK experience erythema, flaking/scaling/dryness and scabbing/crusting at the application site with normal dosing .

Use of sunscreen is encouraged, and patients should minimize or avoid exposure to natural or artificial sunlight (tanning beds or UVA/B treatment) while using Aldara Cream .

Sub-clinical AK lesions may become apparent in the treatment area during treatment and may subsequently resolve .

Description

Aldara ™ is the brand name for imiquimod which is an immune response modifier. where can i buy aldara cream Each gram of the 5% cream contains 50 mg of imiquimod in an off-white oil-in-water vanishing cream base consisting of isostearic acid, cetyl alcohol, stearyl alcohol, white petrolatum, polysorbate 60, sorbitan monostearate, glycerin, xanthan gum, purified water, benzyl alcohol, methylparaben, and propylparaben.

Chemically, imiquimod is 1-(2-methylpropyl)-1 H -imidazo quinolin-4-amine. Imiquimod has a molecular formula of C ₁₄ H ₁₆ N ₄ and a molecular weight of 240.3. Its structural formula is:

Abstract

Background: Increasing evidence suggests imiquimod may be a safe therapeutic option for the treatment of actinic keratosis (AK). http://clinicalinfo.hiv.gov/en/drugs/imiquimod/cream-5 The diagnosis and assessment of most AK lesions is made clinically, without histologic confirmation.

Objective: A phase III, randomized, double-blind, parallel group, vehicle-controlled study evaluated the efficacy of imiquimod 5% cream compared with vehicle in the treatment of AK lesions on the face and balding scalp including pretreatment and posttreatment biopsy specimens.

Methods: A total of 286 patients at 18 centers in 6 European countries with histologically confirmed AK were randomized to either imiquimod 5% cream or vehicle cream. Study cream was applied once per day, 3 days per week, for 16 weeks. Clearance of AK lesions was clinically and histologically assessed at an 8-week posttreatment visit.

Results: The complete clearance rate for the imiquimod group was 57.1% versus 2.2% for the vehicle group (P or =75% reduction in baseline lesions) for the imiquimod group was 72.1% versus 4.3% for the vehicle group (P Conclusion: Imiquimod 5% cream used 3 times per week for 16 weeks is an effective treatment for AK. Clinical clearance was established by both clinical observation and histologic analysis.